Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded up 3.1% on Monday . The company traded as high as $5.52 and last traded at $5.37, with a volume of 590,002 shares. The stock had previously closed at $5.21.

A number of equities research analysts have recently weighed in on the company. Guggenheim reaffirmed a “buy” rating and set a $12.00 price target on shares of Aralez Pharmaceuticals in a research note on Monday, August 15th. Chardan Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Aralez Pharmaceuticals in a research note on Sunday, August 14th.

The firm’s 50-day moving average price is $3.93 and its 200 day moving average price is $4.25. The company’s market cap is $358.83 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The company earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. The firm’s quarterly revenue was up 142.3% on a year-over-year basis. On average, analysts predict that Aralez Pharmaceuticals Inc. will post ($0.98) earnings per share for the current fiscal year.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.